Addressing Challenging Atypical Patients With OAB: Case Discussions (CME/CE Webcast)
Activity Description and Purpose
Target Audience
This educational activity is intended for urologists, urogynecologists, physician assistants, nurse practitioners, nurses, and other clinicians caring for patients with overactive bladder.
Learning Objectives
After completing this activity, participants will be better able to:
- Identify central nervous system effects of anticholinergic agents used to treat overactive bladder
- Recount findings of clinical trial data on new treatments for overactive bladder
- Design appropriate evidence-based treatment strategies for complex patients with overactive bladder
Faculty
Benjamin M. Brucker, MD (Chair) | |
Aqsa A. Khan, MD Assistant Professor Associate Program Director, Urology Residency Department of Urology Mayo Clinic Phoenix, Arizona |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Benjamin M. Brucker, MD, is an advisory board member of AbbVie Inc, Palette Life Sciences, Inc, Sumitomo Pharma America, and Watkins-Conti Products; is on the speakers bureau for AbbVie Inc, Solv Wellness, and Sumitomo Pharma America; and is a contracted researcher for AbbVie Inc and Sumitomo Pharma America.
Aqsa A. Khan, MD, has no relevant commercial relationships to disclose.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
Satisfactory Completion
Learners must take the pretest, view the webcast, and complete a posttest and evaluation form to receive a certificate of completion. Your session must be viewed in its entirety. Partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
For Physicians
ACCME Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For Nurses
Interprofessional Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by MedEdicus LLC and Amedco LLC. Amedco LLC is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.
Nursing Credit
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Sumitomo Pharma America.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Fee Information
There is no fee for this educational activity.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Amedco LLC, or Sumitomo Pharma America.
This CME/CE activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 300.3
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation